Azenta (AZTA) Expected to Announce Earnings on Wednesday

Azenta (NASDAQ:AZTA) is expected to be releasing its Q1 2026 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of $0.11 per share and revenue of $146.89 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 8:30 AM ET.

Azenta (NASDAQ:AZTA) last released its quarterly earnings results on Friday, November 21st. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.01. Azenta had a positive return on equity of 1.40% and a negative net margin of 10.01%.The firm had revenue of $159.19 million for the quarter, compared to analysts’ expectations of $156.76 million. During the same quarter last year, the firm posted $0.18 EPS. The company’s revenue was up 5.7% compared to the same quarter last year. On average, analysts expect Azenta to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Azenta Trading Up 0.7%

Shares of NASDAQ AZTA opened at $40.13 on Wednesday. The business has a 50-day moving average of $36.20 and a 200-day moving average of $32.69. The firm has a market capitalization of $1.85 billion, a price-to-earnings ratio of -30.87 and a beta of 1.32. Azenta has a 12 month low of $23.91 and a 12 month high of $55.63.

Azenta announced that its Board of Directors has initiated a stock repurchase plan on Wednesday, December 10th that authorizes the company to buyback $250.00 million in shares. This buyback authorization authorizes the company to repurchase up to 14.9% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Hedge Funds Weigh In On Azenta

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mercer Global Advisors Inc. ADV purchased a new position in shares of Azenta in the third quarter valued at about $233,000. Creative Planning increased its holdings in Azenta by 19.7% during the 3rd quarter. Creative Planning now owns 10,514 shares of the company’s stock valued at $302,000 after purchasing an additional 1,733 shares during the period. Evergreen Capital Management LLC bought a new position in Azenta during the 2nd quarter valued at approximately $209,000. Canada Pension Plan Investment Board bought a new position in Azenta during the 2nd quarter valued at approximately $225,000. Finally, Amundi lifted its holdings in Azenta by 247.1% in the 2nd quarter. Amundi now owns 9,925 shares of the company’s stock worth $326,000 after buying an additional 7,066 shares during the period. 99.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on AZTA shares. TD Cowen reissued a “hold” rating on shares of Azenta in a report on Thursday, January 8th. Weiss Ratings restated a “sell (e+)” rating on shares of Azenta in a research report on Monday, December 22nd. Evercore ISI set a $50.00 price objective on Azenta in a report on Monday, January 5th. Wall Street Zen upgraded Azenta from a “hold” rating to a “buy” rating in a research report on Saturday, January 3rd. Finally, Raymond James Financial boosted their target price on Azenta from $35.00 to $45.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 25th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Azenta has a consensus rating of “Hold” and an average price target of $41.83.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.